AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 NOV 3 - (NewsRx.com & NewsRx.net) -- Researchers suggest that the incidence of severe Plasmodium falciparum malaria is a useful primary endpoint for vaccine efficacy trials.
"Potential endpoints for blood stage malaria vaccine efficacy trials include uncomplicated malaria disease, which is hard to differentiate from other febrile illnesses, and mortality, which requires prohibitively large sample sizes. Strictly defined severe malaria predicts malaria-associated mortality where case fatality rates are known. To assess the suitability of severe malaria as a trial endpoint, we conducted a census in 1999 and measured the incidence of severe malaria from 1999 to 2001 in Bandiagara, Mali," scientists in the United States and Mali report.
"The annual incidence of severe malaria in children
Lyke and associates published their study in Vaccine (Incidence of severe Plasmodium falciparum malaria as a primary endpoint for vaccine efficacy trials in Bandiagara, Mali. Vaccine, 2004;22(23-24):3169-3174).
For additional information, contact Christopher V. Plowe, Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore ...